Senesco Technologies, Inc.

Sensco Technologies, Inc.

Senesco, Inc.

Catherine Taylor

John E Thompson

Dominic O Cliche

Tzann-Wei Wang

John C Carlson

Richard Narayansingh

Larry Petrov

John Gerard Flanagan

Elizabeth Heikkila

Adrienne Boone

Bruce C Galton

Charles A Dinarello

Richard S Dondero

Leonid Reznikov

Shelley Culp-Stewart

Michelle Senchyna

Marianne Hopkins

Marianne Kaup

Zhenyu Cheng

Zhong Sun

Dominic Cliché

Diane Michelle Senchyna

Benjamin Pomerantz

Diana Michelle Senchyna

Elisabeth M Heikkila

Dominic 75 Old Chicopee Drive Cliche

The present invention relates to apoptosis specific eucaryotic initiation factor 5A (eIF-5A), referred to as apoptosis-specific eIF-5A or eIF5A1, nucleic acids and polypeptides and methods for inhibiting or suppressing apoptosis in cells using antisense nucleotides or siRNAs to inhibit expression of apoptosis-specific eIF-5A. The invention also relates to suppressing or inhibiting expression of pro-inflammatory cytokines or inhibiting activation of NFkB by inhibiting expression of apoptosis-specific eIF-5A.

Inhibition of apoptosis-specific eIF-5A(eIF-5A1&#x2033;) with antisense oligonucleotides and siRNA as anti-inflammatory therapeutics

The present invention relates to the combinatorial use of an siRNA targeted against an endogenous gene to knock out or knock down expression of the endogenous gene in a host and a delivery of a polynucleotide encoding the gene in a delivery vehicle/expression vector to the host to provide expression in the host of the protein encoded by the polynucleotide.

Compositions comprising siRNA and plasmids

The present invention relates to the combinatorial use of an siRNA targeted against an endogenous gene to knock out or knock down expression of the endogenous gene in a host and a delivery of a polynucleotide encoding the gene in a delivery vehicle/expression vector to the host to provide expression in the host of the protein encoded by the polynucleotide. The present invention also relates to a truncated form of eIF-5A1 that is useful for inducing apoptosis and killing of cells, especially cancer cells in a mammal.

Use of a truncated eIF-5A1 polynucleotide to induce apoptosis in cancer cells

The present invention relates to apoptosis specific eucaryotic initiation factor 5A (eIF-5A), referred to as apoptosis factor 5A1 or simply factor 5A1, apoptosis factor 5A1 nucleic acids and polypeptides and methods for inhibiting or suppressing apoptosis in cells using antisense nucleotides or siRNAs to inhibit expression of factor 5A1. The invention also relates to suppressing or inhibiting expression of pro-inflammatory cytokines by inhibiting expression of apoptosis factor 5A.

siRNA useful to supress expression of EIF-5A1

The present invention relates to isolated and/or purified rat apoptosis-specific eucaryotic initiation Factor-5A (eIF-5A) and deoxyhypusine synthase (DHS) nucleic acids and polypeptides. The present invention also relates to methods of modulating apoptosis using apoptosis-specific eIF-5A and DHS, and antisense oligonucleotides and expression vectors of apoptosis-specific eIF-5A and DHS useful in such methods.

Method for inducing apoptosis using apoptosis-specific EIF5-A

Expression vector encoding apoptosis-specific eIF-5A

Use of antisense oligonucleotides or siRNA to suppress expression of eIF-5A1

The present invention provides methods for preventing retinal ganglion cell death in the glaucomatous eye and methods for suppressing apoptosis-specific eIF5A1 expression through the use of antisense oligonucleotides targeted to human apoptosis-specific eIF5A1.

Suppression of eIF5A1 expression by the use of antisense oligonucleotides for the prevention of retinal cell death in the glaucomatous eye

The present invention provides methods of identifying an incidence of ischemia in mammalian tissue, particularly mammalian heart tissue. Further, a method of reducing apoptosis in mammalian tissue, preferably heart tissue, is provided. These methods involve measuring and comparing the gene expression levels of both apoptosis-specific eIF-5A and proliferating eIF-5A and correlating an incidence of ischemia when the expression level of apoptosis-specific eIF-5a is higher than proliferating eIF-5A. In the method of reducing apoptosis in mammalian tissue, there is provided an agent that inhibits expression of apoptosis-specific eIF-5A. Preferred agents are antisense oligonucleotides to human apoptosis-specific eIF-5A.

Nucleic acids, polypeptides, and methods for modulating apoptosis

Nucleic acids, polypeptides, compositions, and methods for modulating apoptosis

Genes encoding an apoptosis-induced eukaryotic initiation Factor-5A (eIF-5A) and an apoptosis-induced deoxyhypusine synthase (DHS), whose expressions are induced by the onset of apoptosis, are identified. The DHS gene and the eIF-5A gene, alone or in combination, as well as inhibitors of the DHS reaction, are used to modulate apoptosis in animals and humans. For example, modulation of apoptosis in cells of animals and humans is achieved by introduction of a gene or gene fragment encoding apoptosis-induced eIF-5A, apoptosis-induced DHS, or both into the animal or human cell in antisense orientation.

DNA encoding apoptosis-induced eucaryotic initiation factor-5A and deoxyhypusine synthase and a method for controlling apoptosis in animals and humans

Growing community of inventors

Waterloo, Canada

Catherine Taylor